Medigene AG: Preliminary result of the rights offering and start of the private placement

Planegg/Martinsried (pta/08.05.2024/11:55 UTC+2)

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focused on the research and development of T-cell immunotherapies for solid tumors, hereby announces the preliminary results of the capital increase resolved on April 22, 2024, to increase the share capital from EUR 24,562,658.00 by up to EUR 4,912,531.00 to up to EUR 29,475,189.00 and announces that 4,152,247 new shares were subscribed for as part of the subscription rights offer by shareholders exercising their subscription and oversubscription rights. This reflects a subscription ratio of 84.52%.

Following this preliminary result of the rights offering, the private placement will now commence with immediate effect, in which the up to 760,284 new shares not subscribed for by existing shareholders or holders of subscription rights will be offered for purchase to selected investors within the European Union. The new shares not subscribed for in the private placement will be acquired by an investor within the framework of a backstop agreement.

Against this background, it is certain that the capital measure will be fully subscribed and that the company will receive gross issue proceeds of approximately EUR 5.9 million.

The gross proceeds of the offering will be used to fund operations and to advance work towards clinical development of the company’s lead program, MDG1015.

Following the entry of the capital increase in the commercial register of the Munich Local Court, the company’s new share capital amounts to EUR 29,475,189.00 and is divided into 29,475,189 no-par value registered shares.

The Company is currently evaluating the impact on its cash runway.

NOT FOR DISTRIBUTION, TRANSMISSION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

(end)

emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg/Martinsried
country: Germany
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
e-mail: investor@medigene.com
website: medigene.com

ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

source: https://www.pressetext.com/news/20240508020